Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia
Recruiting
Observational Study
Preeclampsia
Gestational Hypertension
Hypertensive Disorders of Pregnancy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Healthy Volunteers Welcome
You do not need to have the condition being studied to take part.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 45
- Sex
- Female
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Ammar Jassim Abed · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
IInclusion Criteria:
* Pregnant women between 20 and 36 weeks of gestation
* Age between 18 and 45 years
* Attending the antenatal clinic at the study site
Exclusion Criteria:
* Chronic hypertension
* Renal disease
* Diabetes mellitus
* Multiple gestations
* Autoimmune disorders
Contacts